JP2022505094A5 - - Google Patents
Info
- Publication number
- JP2022505094A5 JP2022505094A5 JP2021521000A JP2021521000A JP2022505094A5 JP 2022505094 A5 JP2022505094 A5 JP 2022505094A5 JP 2021521000 A JP2021521000 A JP 2021521000A JP 2021521000 A JP2021521000 A JP 2021521000A JP 2022505094 A5 JP2022505094 A5 JP 2022505094A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- complex
- sequence
- numbered
- relation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746804P | 2018-10-17 | 2018-10-17 | |
| US62/746,804 | 2018-10-17 | ||
| PCT/IB2019/058777 WO2020079586A1 (en) | 2018-10-17 | 2019-10-15 | Modified cytomegalovirus proteins and stabilized complexes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505094A JP2022505094A (ja) | 2022-01-14 |
| JP2022505094A5 true JP2022505094A5 (cg-RX-API-DMAC7.html) | 2022-10-31 |
| JP7584405B2 JP7584405B2 (ja) | 2024-11-15 |
Family
ID=68296588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521000A Active JP7584405B2 (ja) | 2018-10-17 | 2019-10-15 | 改変されたサイトメガロウイルスタンパク質及び安定化された複合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11932669B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3866845A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7584405B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113271968B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021006812A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3116175A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021004273A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020079586A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245611A1 (en) | 2020-06-05 | 2021-12-09 | Glaxosmithkline Biologicals Sa | Modified betacoronavirus spike proteins |
| JP2023553854A (ja) | 2020-12-02 | 2023-12-26 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ドナー鎖補完性fimh |
| US20250325656A1 (en) * | 2022-05-20 | 2025-10-23 | Glaxosmithkline Biologicals Sa | Modified varicella zoster virus glycoprotein e proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920701453A (ko) | 1989-03-17 | 1992-08-11 | 미리엄 디. 멕코나헤이 | 유전자발현의 외부조절 |
| US5362865A (en) | 1993-09-02 | 1994-11-08 | Monsanto Company | Enhanced expression in plants using non-translated leader sequences |
| US5693506A (en) | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| WO2001000648A1 (en) | 1999-06-25 | 2001-01-04 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| US7704510B2 (en) | 2006-06-07 | 2010-04-27 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| PE20141398A1 (es) | 2008-07-16 | 2014-10-18 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
| US8778359B2 (en) | 2008-07-30 | 2014-07-15 | Emergent Biosolutions Inc. | Stable anthrax vaccine formulations |
| US9950062B2 (en) | 2009-09-02 | 2018-04-24 | Glaxosmithkline Biologicals Sa | Compounds and compositions as TLR activity modulators |
| EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| AU2013286093B2 (en) | 2012-07-06 | 2018-01-04 | Novartis Ag | Complexes of cytomegalovirus proteins |
| EP3269388A1 (en) | 2012-10-30 | 2018-01-17 | Pfizer Inc. | Recombinant particle based vaccines against human cytomegalovirus infection |
| RS61993B1 (sr) * | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| MX2016014660A (es) | 2014-05-08 | 2017-02-28 | Pfizer | Medios y metodos para el tratamiento de cmv. |
| BE1023213B1 (fr) | 2014-05-27 | 2016-12-21 | Glaxosmithkline Biologicals Sa | Complexes issus du cytomegalovirus et leurs utilisations |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| EP3364981A4 (en) * | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
| US11833198B2 (en) | 2017-03-28 | 2023-12-05 | Children's Hospital Medical Center | Norovirus S particle based vaccines and methods of making and using same |
-
2019
- 2019-10-15 WO PCT/IB2019/058777 patent/WO2020079586A1/en not_active Ceased
- 2019-10-15 EP EP19790842.9A patent/EP3866845A1/en active Pending
- 2019-10-15 CA CA3116175A patent/CA3116175A1/en active Pending
- 2019-10-15 JP JP2021521000A patent/JP7584405B2/ja active Active
- 2019-10-15 CN CN201980084001.XA patent/CN113271968B/zh active Active
- 2019-10-15 BR BR112021006812-0A patent/BR112021006812A2/pt not_active IP Right Cessation
- 2019-10-15 MX MX2021004273A patent/MX2021004273A/es unknown
-
2021
- 2021-04-06 US US17/223,207 patent/US11932669B2/en active Active
-
2024
- 2024-02-07 US US18/435,026 patent/US12384819B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3319633B1 (en) | Vaccine against rsv | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| JP2018510622A5 (cg-RX-API-DMAC7.html) | ||
| FI3247722T3 (fi) | Sytomegalovirusantigeenejä ja niiden käyttöjä | |
| WO2010135491A3 (en) | Fibroblast growth factor mutants having improved functional half-life and methods of their use | |
| NZ603016A (en) | Novel immunotherapy against several tumors including neuronal and brain tumors | |
| MY150105A (en) | A novel surface exposed haemophilus influenzae protein (protein e; pe) | |
| EP4623996A3 (en) | COMPOSITIONS AND METHODS FOR IDENTIFYING TUMOR-SPECIFIC NEOANTIGENS | |
| CY1422A (en) | Recombinant dna,hoats transformed with it and polypeptides produced by the hosts;processes for their preparation;detection processes using the polypeptides;compositions and means containing the polypeptides;dna sequences | |
| JP2010504096A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0411363A (pt) | seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas | |
| RU2020116307A (ru) | Модифицированные белки vp1 норовируса и vlp, содержащие модифицированные белки vp1 норовируса | |
| FI2956471T3 (fi) | Il-1-beetan estäjän koostumus ja sen käyttö | |
| JP2020518249A5 (cg-RX-API-DMAC7.html) | ||
| WO2021239838A3 (en) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes | |
| PE20020857A1 (es) | Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras | |
| JP2010535504A5 (cg-RX-API-DMAC7.html) | ||
| BR112017022076A2 (pt) | fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas | |
| CN110746496A (zh) | 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用 | |
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| RU2017104284A (ru) | Выделенные полипептиды cd44 и их применение | |
| JP2023510544A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524420A5 (cg-RX-API-DMAC7.html) |